TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24728846
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) - 6000 impulses (energy flux density, 0.11 mJ/mm²) in three sessions after local anesthesia.
Study: 19962288
Drug: Silexan (lavender
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silexan (lavender oil preparation), 6-week intake
Study: 18541280
Drug: Tafenoquine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 200 mg bid for 3 days
Study: 18541280
Drug: Tafenoquine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 400 mg od for 3 days
Study: 18541280
Drug: Primaquine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine plus doxycycline (22.5 mg + 100 mg daily for 14 days)
Study: 18541280
Drug: Tafenoquine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 200 mg od for 3 days
Study: 8869096
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care plus MLT (20 mg/day orally in the evening)
Study: 8465554
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii (S.b.) 250 mg t.i.d. for 7 weeks
Study: 27376907
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel (10 ml)
Study: 19274410
Drug: Focus Monthly
Normalized name: Ficus benghalensis bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focus Monthly (Ciba Vision)
Study: 17146319
Drug: ORAL rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORAL rehydration
Study: 10924977
Drug: Conventionally fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally fractionated (cf) treatment: 60 Gy over 6 weeks (n = 79)
Study: 1405361
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of hypertension to blood pressure values within the normal range
Study: 1405361
Drug: Low-protein diets
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diets with ketoacid supplement
Study: 1405361
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment of hyperlipidemia
Study: 31197986
Drug: MenACWY-CRM197 conjugate
Normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM197 conjugate vaccine
Study: 31197986
Drug: MenACWY-DT conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MenACWY-DT conjugate vaccine
Study: 29100777
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tibial tubercle lateralization and patella alta
Study: 27358434
Drug: High-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose edoxaban regimen (HDER) 60 mg daily or 30 mg daily for CrCl 30-50 mL/min
Study: 27358434
Drug: High-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose edoxaban regimen (HDER)
Study: 20438400
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 0.033 mg/kg/day
Study: 20438400
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 0.067 mg/kg/day
Study: 12016800
Drug: Indapamide (2.5‐7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (2.5‐7.5 mg.d‐1)
Study: 12016800
Drug: Dihydro-chlorothiazide (50‐70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydro-chlorothiazide (50‐70 mg.d‐1)
Study: 12016800
Drug: Carbamazepine (150‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (150‐300 mg.d‐1)
Study: 8824659
Drug: Polyunsaturated phosphatidyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyunsaturated phosphatidyl choline (900 mg orally daily)
Study: 1614464
Drug: Standard immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immune globulin (400 mg per kilogram of body weight)
Study: 1614464
Drug: Core-lipopolysaccharide hyperimmune
Normalized name: sulfated mucopolysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core-lipopolysaccharide hyperimmune globulin (400 mg per kilogram)
Study: 1614464
Drug: Placebo (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (25 percent albumin, 8 ml per kilogram)
Study: 26852095
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) combined with maintenance antidepressant medication (mADM)
Study: 26852095
Drug: Maintenance antidepressant
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance antidepressant medication (mADM)
Study: 19671565
Drug: Injection Troynoxa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Troynoxa (enoxaparin sodium 40 mg/0.4 mL)
Study: 19671565
Drug: Injection Clexane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Clexane (enoxaparin sodium 40 mg/0.4 mL)
Study: 12190161
Drug: Midazolam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2 mg <70 kg b.w. or 3 mg >70 kg b.w.) and propofol (median dose 80 mg, range 40-150)
Study: 12190161
Drug: Midazolam (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (median dose 5 mg, range 3-7) and pethidine (75 mg, range 50-125)
Study: 9973029
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with heparin (5,000 U bolus, 1,000 to 1,300 U/h infusion)
Study: 9973029
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with hirudin (0.1 to 0.6 mg/kg bolus, 0.1 to 0.2 mg/kg/h infusion)
Study: 9973029
Drug: Intensity of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity of anticoagulation (heparin or hirudin)
Study: 26709238
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch 10 mg/16 hr for 8 weeks
Study: 26709238
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch 15 mg/16 hr for 8 weeks
Study: 22654429
Drug: 7-day conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day conventional triple therapy
Study: 22654429
Drug: 10-day conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day conventional triple therapy
Study: 22654429
Drug: 14-day conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day conventional triple therapy
Study: 19464125
Drug: Hydromorphone (HYD)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone (HYD) 12 mg IM
Study: 19464125
Drug: Hydromorphone (HYD)
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone (HYD) 24 mg IM
Study: 17364587
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of olmesartan (20 mg)
Study: 17364587
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of olmesartan (20 mg)
Study: 15164513
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antianginal drugs and membran‐oprotective drugs (MPD)
Study: 15164513
Drug: Antianginal drugs
Normalized name: ANTIANGINALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antianginal drugs alone
Study: 11136274
Drug: naproxen (500-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (500-1000 mg/day) and misoprostol (200 microg b.d.)
Study: 11136274
Drug: nabumetone (1000-1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: nabumetone (1000-1500 mg/day) and placebo misoprostol
Study: 2927553
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase with 5 X 10(5) IU (SK‐i.v.) in group A before transport
Study: 2927553
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase with 5 X 10(5) IU (SK‐i.v.) in group B after transport
Study: 30894394
Drug: Self-injection training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-injection training for DMPA-SC
Study: 28219801
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) - 10 cycles, using DIOMED Light or PhotoDYN Light
Study: 21681863
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (TAPS)
Study: 16378915
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea capsules
Study: 12946074
Drug: Silica-coated ceramic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silica-coated ceramic surface with Panavia 21 and silane/bonding agent
Study: 12946074
Drug: Untreated ceramic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated ceramic surface with Panavia 21 and silane/bonding agent
Study: 11776174
Drug: One antibiotic
Normalized name: Neomycin Sulfate 3.5 mg in 1 g / Polymyxin B Sulfate 10000 [iU] in 1 g / Pramoxine Hydrochloride 10 mg in 1 g TOPICAL CREAM [CAREONE Antibiotic Plus Pain Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: One antibiotic given for three days (group B)
Study: 11776174
Drug: Only once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Only once antibiotic used (group C)
Study: 11776174
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic given (group A)
Study: 11776174
Drug: Both cesarean
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both cesarean section and antibiotics
Study: 8383058
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg x 2 (in reference group)
Study: 8383058
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg x 2
Study: 8383058
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg x 3
Study: 3087862
Drug: Interferon (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (5 X 10(6) IU) administered once daily subcutaneously during a five day treatment period followed by a three month maintenance period (1 X 10(6) IU three times weekly)
Study: 23292622
Drug: Buspirone (20-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (20-30 mg/day depending on weight)
Study: 15699292
Drug: DHEA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA therapy (90 mg/d for 3 weeks and 450 mg/d for 3 weeks)
Study: 18425654
Drug: Tobacco cessation
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco cessation intervention delivered by dental hygienists during cleaning visits; specific components included video and written materials; details on dosage and duration not specified.
Study: 1717688
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release formulation of tiaprofenic acid (two 300 mg capsules once a day)
Study: 1717688
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation of tiaprofenic acid (one 300 mg tablet taken twice a day)
Study: 17917317
Drug: Valsartan (40‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (40‐80 mg/day)
Study: 17917317
Drug: Nifedipine (20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20‐40 mg/day)
Study: 9620489
Drug: Topical agent
Normalized name: topical agent combination no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical agent
Study: 7882454
Drug: Oral amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiodarone (600-800 mg daily) with infusional doxorubicin (60 mg/m2 over 96 h)
Study: 7882454
Drug: Oral amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiodarone (600-800 mg daily) with infusional vinblastine (8.5 mg/m2 over 120 h)
Study: 2142915
Drug: Ipratropium (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium (80 micrograms via metered dose inhaler with each salbutamol treatment, 6 to 8 times per day)
Study: 2142915
Drug: Placebo (via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (via metered dose inhaler with each salbutamol treatment, 6 to 8 times per day)
Study: 30316635
Drug: <350 mg/dL
Approvals — FDA: no, EMA: no, PMDA: no
Description: <350 mg/dL (moderate control)
Study: 30316635
Drug: <600 mg/dL
Approvals — FDA: no, EMA: no, PMDA: no
Description: <600 mg/dL (loose control)
Study: 26083474
Drug: 10-Valent Pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-Valent Pneumococcal Non-Typeable Haemophilus influenza Protein D Conjugate Vaccine (PHiD-CV)
Study: 11332239
Drug: Rofecoxib (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (maximum single dose 12.5 mg, cumulative dose 25 mg)
Study: 7889606
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection after fine needle aspiration (Group 2)
Study: 7889606
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection (Group 3)
Study: 7889606
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection (Group 2)
Study: 12855921
Drug: Transdermal ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal ketoprofen applied TID to quadriceps
Study: 12855921
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied TID to quadriceps
Study: 10911654
Drug: Icodextrin (I)
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icodextrin (I) solution
Study: 10911654
Drug: Icodextrin (I)
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Icodextrin (I) solution during peritonitis (P)
Study: 10911654
Drug: Glucose (G)
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose (G) solution
Study: 10911654
Drug: Glucose (G)
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose (G) solution during peritonitis (P)
Study: 8616558
Drug: Aerosolized bronchodilator
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized bronchodilator
Study: 6088396
Drug: Fresh human
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh human milk (200 ml per day)
Study: 24659069
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation (IVS) with midazolam/fentanyl
Study: 20097931
Drug: Tocilizumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (4 or 8 mg/kg)
Study: 9145453
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated controls)
Study: 9145453
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of antioxidant vitamins
Study: 18059393
Drug: Total antibiotic
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total antibiotic use
Study: 18059393
Drug: Antibiotic use
Normalized name: Antibiotics for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic use by site
Study: 18059393
Drug: Frequency of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency of antibiotic use
Study: 18059393
Drug: Age at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age at first antibiotic use
Study: 17044452
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination (ID group) - 10 microg of recombinant hepatitis B vaccine (Engerix B) intradermally every 2 weeks for a total of 7 doses.
Study: 17044452
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination (IM group) - 40 microg intramuscularly at 0, 1, 2, and 6 months.
Study: 17044452
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination (ID group)
Study: 17044452
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination (IM group)
Study: 12830437
Drug: Daily Hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Hemodialysis (n = 11)
Study: 12830437
Drug: Conventional Thrice-Weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Thrice-Weekly Hemodialysis (Control)
Study: 1583246
Drug: ICI 204,219
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 204,219 (40 mg)
Study: 26608342
Drug: Non-alcohol antimicrobial
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-alcohol antimicrobial mouth rinse containing cetylpyridinium chloride and oral health education
Study: 26608342
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received a package of toothbrush and paste, plus oral hygiene education
Study: 20568432
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (needles at Zusanli (ST 36), Zhongwan (CV 12), Weishu (BL 21), Neiguan (PC 6), once a day)
Study: 20568432
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment (20 mg Omeprazole, once a day)
Study: 12930517
Drug: L-E-GTF
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-E-GTF
Study: 12930517
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (L-E-GTF and Soluble E-GTF)
Study: 15321259
Drug: Intravenous nalmefene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nalmefene 0.25 micro.kg(‐1) every 12 h x 2
Study: 15321259
Drug: Intravenous nalmefene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nalmefene 0.5 microg.kg(‐1) every 12 h x 2
Study: 15321259
Drug: Naloxone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone infusion 48 microg.h(‐1) (1.2 microg.ml(‐1))
Study: 1738553
Drug: Antibiotic eardrops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic eardrops administered to right ears intraoperatively and for 3 days post-surgery
Study: 1738553
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic eardrops (control) administered to left ears
Study: 4006253
Drug: slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow release Nifedipine (srN) 20 mg b.d.
Study: 4006253
Drug: slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow release Nifedipine (srN) 20 mg b.d. plus Acebutolol (A) 400 mg
Study: 29635145
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment discontinuation
Study: 18812115
Drug: 0.1 mL
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL preservative‐free lidocaine hydrochloride 1% injected in the capsular bag during hydrodissection
Study: 18812115
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution (BSS) (control group)
Study: 12913083
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (PPC) with 5-FU (320 mg/m²/day for 5 days) and postoperative chemotherapy with MMC (6 mg/m²) and oral 5-FU (200 mg/day for 6 months)
Study: 12913083
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (PC) with MMC (6 mg/m²) and oral 5-FU (200 mg/day for 6 months)
Study: 12913083
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (PPC)
Study: 12913083
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (PC)
Study: 7572702
Drug: Dietary calcium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary calcium intake of 1768 mg/d (44 mmol/d)
Study: 7572702
Drug: Halving daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halving daily sodium excretion
Study: 7572702
Drug: Urinary sodium
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary sodium excretion
Study: 7572702
Drug: Dietary calcium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary calcium intake and urine sodium excretion
Study: 1951503
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg methylcellulose gel
Study: 1951503
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg controlled-release pessary
Study: 19684236
Drug: Strict glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict glucose control with predominantly meal related insulin using subcutaneous insulin
Study: 19684236
Drug: Strict glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict glucose control with predominantly basal insulin using intravenous insulin
Study: 19684236
Drug: Conventional glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose lowering therapy